PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Pizotifen - Migraine (prevention)
PAD Profile : Pizotifen - Migraine (prevention) Important
Keywords :
cluster headaches, migraine prevention, migraine prophylaxis
Brand Names Include :
Sanomigran
Important Information :
Review existing patients and consider alternative.
Discontinuation of pizotifen requires gradual withdrawal.
Traffic Light Status
Status 1 of 1.
Status :
Green (see narrative)
Formulations :
- Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Type
Document
Review Date
Guidelines
No guidelines returned.
Other Drugs
- Botulinum toxin type A
- Flunarizine dihydrochloride
- Erenumab
- Galcanezumab
- Fremanezumab
- Propranolol hydrochloride
- Topiramate
- Amitriptyline hydrochloride
- Gabapentin
- Pregabalin
- Rimegepant
- Eptinezumab
- Candesartan cilexetil
- Atogepant
- Clonidine hydrochloride
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
10 April 2024
Surrey Heartlands Medicines Safety Committee (MSC)
The Medicine Safety Committee has developed "Pizotifen safety advice" for healthcare professionals to consider when prescribing and monitoring patients on pizotifen
01 July 2015
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
This drug has been agreed as appropriate for initiation in Primary Care and/or continued in Primary Care following a recommendation from specialists in other health care sectors. Following consideration by the PCN, it has been assigned a GREEN traffic light status
Associated BNF Codes
04. Central Nervous System
04.07.04. Antimigraine drugs